Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 15/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 15/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 13/20 | 1.00 |
| ▸ | TTR | P02766 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10946633 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL1824102 | 0.86 | PTGS1 (0.74) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL1824103 | 0.86 | PTGS1 (0.74) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL12567451 | 0.84 | PTGS1 (0.71) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL27620481 | 0.83 | PTGS1 (0.70) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL25314840 | 0.82 | ALOX5 (0.69) | PTGS1PTGS2ALOX5TTR | |
| Enofelast SCHEMBL636264 | 0.79 | PTGS1 (1.00) | PTGS1PTGS2ALOX5TTR | |
| Enofelast SCHEMBL636263 | 0.79 | PTGS1 (1.00) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL10385357 | 0.79 | ALOX5 (1.00) | PTGS1PTGS2ALOX5TTR | |
| SCHEMBL172757 | 0.79 | ALOX5 (0.66) | PTGS1PTGS2ALOX5TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| CN-102369223-A | Molecularly imprinted polymers | COMMW SCIENT IND RES ORG | 2012-03-07 | — | — | CN | disclosed |
| WO-2011075210-A2 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | PTGS1 3544/4885PTGS2 3961/4885ALOX5 1365/4885 |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | PTGS1 3544/4885PTGS2 3961/4885ALOX5 1365/4885 |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | TTR, TTPA, APOB | PTGS1 3544/4885PTGS2 3961/4885ALOX5 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.